Ligand ID: MV2


Drugbank ID:
DB09357
(Dexpanthenol)


Indication:
Injection: Prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus. Intestinal atony causing abdominal distention; postoperative or postpartum retention of flatus, or postoperative delay in resumption of intestinal motility; paralytic ileus.

Get human targets for MV2 in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'MV2'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		1x7q BETA-2-MICROGLOBULIN
HLA, A-11
(Homo
sapiens)		4 / 7
VAL A  12
HIS B  31
LEU A  78
ILE A  23
1.27A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
VAL B1148
HIS B1164
LEU B1030
ILE B1106
1.47A21.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
(SARSr-CoV)		4 / 7
VAL H 135
LEU H 122
TYR H 154
ILE H 111
1.36A21.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2ajf SPIKE PROTEIN
(SARSr-CoV)		4 / 7
ASP F 480
LEU F 478
ILE F 405
ASN F 409
1.41A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
ASP B 187
HIS B  41
TYR B 161
ILE B 136
1.47A21.41
None
ENB  B1145 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASP S 480
LEU S 478
ILE S 405
ASN S 409
1.43A18.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2ghw SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASP C 480
LEU C 478
ILE C 405
ASN C 409
1.43A19.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2gri NSP3
(SARSr)		4 / 7
VAL A  62
LEU A  66
TYR A  43
ILE A  24
1.26A17.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2gri NSP3
(SARSr)		4 / 7
VAL A  62
ASP A  33
LEU A  66
TYR A  43
1.42A17.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 7
VAL D 294
ASP D 239
HIS D 234
ILE D 252
1.27A18.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 7
VAL A 291
HIS B  18
ILE A 269
ASN A 277
1.29A18.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		4 / 7
ASP A 480
LEU A 478
ILE A 405
ASN A 409
1.43A18.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASP E 480
LEU E 478
ILE E 405
ASN E 409
1.40A17.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
VAL B 283
TYR B 279
ILE B 291
ASN B 437
1.41A21.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3d0h SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASP E 480
LEU E 478
ILE E 405
ASN E 409
1.39A17.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3e9s NSP3
(SARSr-CoV)		4 / 7
VAL A 189
TYR A 234
ILE A 315
ASN A 187
1.28A21.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		4 / 7
VAL D  12
HIS E  31
LEU D  78
ILE D  23
1.28A21.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3i6l BETA-2-MICROGLOBULIN
HLA, A-24
(Homo
sapiens)		5 / 7
VAL D  12
ASP D 119
HIS E  31
LEU D  78
ILE D  23
1.53A21.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3r24 2'-O-METHYL
TRANSFERASE
NSP10 AND NSP11
(SARSr-CoV)		4 / 7
VAL A  78
ASP A 102
HIS B  80
ILE B  38
1.45A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3sci SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASP E 480
LEU E 478
ILE E 405
ASN E 409
1.36A18.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3scj ACE2
(Homo
sapiens)		4 / 7
VAL B 283
TYR B 279
ILE B 291
ASN B 437
1.41A19.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
VAL A 581
HIS A 228
LEU A 585
TYR A 516
1.41A21.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASP F 480
LEU F 478
ILE F 405
ASN F 409
1.33A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
VAL D 381
LEU D 329
TYR D 511
ILE D 510
1.33A20.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
VAL D 381
LEU D 329
TYR D 511
ILE D 510
1.29A20.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		5f22 NSP8
(SARSr-CoV)		4 / 7
VAL B 135
LEU B 122
TYR B 154
ILE B 111
1.42A17.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 7
VAL C 381
LEU C 329
TYR C 511
ILE C 510
1.36A20.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 7
VAL O   7
HIS D  26
ILE O  38
ASN O  10
1.44A16.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
VAL A 148
HIS A 164
LEU A  30
ILE A 106
1.54A18.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASP B 480
LEU B 478
ILE B 405
ASN B 409
1.33A15.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		5x5f S PROTEIN
(MERS-CoV)		4 / 7
LEU B 506
TYR C 438
ILE C 433
ASN C 436
1.07A13.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
VAL C 945
ASP A 557
LEU C 948
ASN C 838
1.36A15.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
ASP C 480
LEU C 478
ILE C 405
ASN C 409
1.22A12.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 7
ASP A 119
HIS B  31
LEU A  78
ILE A  23
1.15A22.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		4 / 7
VAL B1164
ASP C 979
LEU B 981
ILE B 973
1.23A18.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
VAL A 148
HIS A 164
LEU A  30
ILE A 106
1.58A24.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6lzg ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ASP A  30
HIS A  34
ILE B 402
ASN B 422
1.43A19.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 7
VAL A 275
ASP A 270
HIS A  65
ILE A  76
1.42A19.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ASP B 187
HIS B  41
TYR B 161
ILE B 136
1.61A23.81
None
3WL  B 401 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
VAL A 148
HIS A 164
LEU A  30
ILE A 106
1.56A23.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL A 330
ASP A 377
LEU B 117
ILE B 107
1.78A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 826
ASP A 867
LEU A 828
ILE A 726
1.23A12.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASP A6928
HIS A6867
ILE A6910
ASN A6899
1.66A
SAM  A7104 (-3.8A)
None
None
SAM  A7104 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
VAL A 148
HIS A 164
LEU A  30
ILE A 106
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
ASP C6928
HIS C6867
ILE C6910
ASN C6899
1.65A18.97
SAM  C7105 ( 3.7A)
None
None
SAM  C7105 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
ASP A6928
HIS A6867
ILE A6910
ASN A6899
1.64A18.97
SAM  A7102 ( 3.7A)
None
None
SAM  A7102 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL A6916
ASP C7091
LEU A6909
TYR A6950
1.64A18.97
None
None
None
FMT  A7109 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL A7092
HIS A6917
LEU C6909
ILE A6910
1.44A18.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 7
VAL C6876
ASP C6900
HIS D4333
ILE D4291
1.67A18.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL C7092
HIS C6917
LEU A6909
ILE C6910
1.55A18.97
None
FMT  C7113 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL C6916
ASP A7091
LEU C6909
TYR C6950
1.66A18.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
HIS C 272
LEU C 118
TYR C 296
ILE C 300
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
HIS A 272
LEU A 118
TYR A 296
ILE A 300
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
HIS B 272
LEU B 118
TYR B 296
ILE B 300
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wiq NSP8
(SARS-CoV-2)		4 / 7
VAL B 130
LEU B 117
TYR B 149
ILE B 106
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASP A6928
HIS A6867
ILE A6910
ASN A6899
1.63A
SAH  A7102 (-3.7A)
None
None
SAH  A7102 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL A6916
ASP C7091
LEU A6909
TYR A6950
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL C6916
ASP A7091
LEU C6909
TYR C6950
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASP C6928
HIS C6867
ILE C6910
ASN C6899
1.63A
SAH  C7102 (-3.7A)
None
None
SAH  C7102 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
VAL C6876
ASP C6900
HIS D4333
ILE D4291
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
ASP C6928
HIS C6867
ILE C6910
ASN C6899
1.63A
SFG  C7103 ( 3.7A)
None
None
SFG  C7103 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
VAL A6916
ASP C7091
LEU A6909
TYR A6950
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
VAL A7092
HIS A6917
LEU C6909
ILE A6910
1.50A
 NA  A7102 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
ASP A6928
HIS A6867
ILE A6910
ASN A6899
1.63A
SFG  A7103 ( 3.6A)
None
None
SFG  A7103 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 7
VAL C6876
ASP C6900
HIS D4333
ILE D4291
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
VAL C7092
HIS C6917
LEU A6909
ILE C6910
1.57A
None
FMT  C7108 ( 4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
VAL C6916
ASP A7091
LEU C6909
TYR C6950
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
VAL A 142
ASP A  79
TYR A 179
ILE A  72
1.73A
None
EDO  A 406 (-4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
VAL B 142
ASP B  79
TYR B 179
ILE B  72
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
VAL A6876
ASP A6900
HIS B4333
ILE B4291
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASP A6928
HIS A6867
ILE A6910
ASN A6899
1.63A
SAH  A7101 (-3.7A)
None
None
SAH  A7101 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wqd NSP8
(SARS-CoV-2)		4 / 7
VAL D 130
LEU D 117
TYR D 149
ILE D 106
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wqd NSP8
(SARS-CoV-2)		4 / 7
VAL B 130
LEU B 117
TYR B 149
ILE B 106
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
HIS A 272
LEU A 118
TYR A 296
ILE A 300
1.59A
PO4  A 502 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
VAL A 188
TYR A 233
ILE A 314
ASN A 186
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
VAL A 148
HIS A 164
LEU A  30
ILE A 106
1.55A18.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL D 130
LEU D 117
TYR D 149
ILE D 106
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
VAL A 148
HIS A 164
LEU A 177
ILE A 136
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		7btf NSP7
NSP8
(SARS-CoV-2)		4 / 7
VAL D 115
ASP C  67
TYR D 149
ILE D 120
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		7btf NSP8
(SARS-CoV-2)		4 / 7
VAL D 130
LEU D 117
TYR D 149
ILE D 106
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AVP_A_MV2A313_1
(PANTOTHENATE KINASE)		7bv1 NSP7
NSP8
(SARS-CoV-2)		4 / 7
VAL C  53
ASP D 101
LEU D 103
ILE C  39
1.80A
None